377 related articles for article (PubMed ID: 28025037)
1. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
Nichols DP; Happoldt CL; Bratcher PE; Caceres SM; Chmiel JF; Malcolm KC; Saavedra MT; Saiman L; Taylor-Cousar JL; Nick JA
J Cyst Fibros; 2017 May; 16(3):358-366. PubMed ID: 28025037
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
Nick JA; Moskowitz SM; Chmiel JF; Forssén AV; Kim SH; Saavedra MT; Saiman L; Taylor-Cousar JL; Nichols DP
Ann Am Thorac Soc; 2014 Mar; 11(3):342-50. PubMed ID: 24476418
[TBL] [Abstract][Full Text] [Related]
3. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
[TBL] [Abstract][Full Text] [Related]
4. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
Hansen C; Skov M
Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
[TBL] [Abstract][Full Text] [Related]
5. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
[TBL] [Abstract][Full Text] [Related]
7. Testing the effects of combining azithromycin with inhaled tobramycin for
Nichols DP; Singh PK; Baines A; Caverly LJ; Chmiel JF; GIbson RL; Lascano J; Morgan SJ; Retsch-Bogart G; Saiman L; Sadeghi H; Billings JL; Heltshe SL; Kirby S; Kong A; Nick JA; Mayer-Hamblett N;
Thorax; 2022 Jun; 77(6):581-588. PubMed ID: 34706982
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
[TBL] [Abstract][Full Text] [Related]
9. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
Dasenbrook EC; Konstan MW; VanDevanter DR
J Cyst Fibros; 2015 May; 14(3):370-5. PubMed ID: 25496726
[TBL] [Abstract][Full Text] [Related]
10. A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.
Plant BJ; Downey DG; Eustace JA; Gunaratnam C; Haworth CS; Jones AM; McKone EF; Peckham DG; Ketchell RI; Bilton D
J Cyst Fibros; 2017 Nov; 16(6):695-701. PubMed ID: 28392014
[TBL] [Abstract][Full Text] [Related]
11. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
[TBL] [Abstract][Full Text] [Related]
12. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
[No Abstract] [Full Text] [Related]
13. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
Antoniu S
Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
[TBL] [Abstract][Full Text] [Related]
14. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
15. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.
Nichols DP; Odem-Davis K; Cogen JD; Goss CH; Ren CL; Skalland M; Somayaji R; Heltshe SL
Am J Respir Crit Care Med; 2020 Feb; 201(4):430-437. PubMed ID: 31661302
[No Abstract] [Full Text] [Related]
17. Aerosolized antibiotics in cystic fibrosis: an update.
Fiel SB
Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
[TBL] [Abstract][Full Text] [Related]
18. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
[TBL] [Abstract][Full Text] [Related]
20. Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach.
Guglani L; Abdulhamid I; Ditouras J; Montejo J
Ann Pharmacother; 2012 Oct; 46(10):e25. PubMed ID: 23012384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
